shivaani kummar ohsu email

NPI 1053612341 Dr. Shivaani Kummar in Portland - Address, Medicare Affiliated Hospitals Medical Group Practices Practice Location 3181 Sw Sam Jackson Park Rd Portland, Oregon 97239-3011 Map and Directions Phone: (503) 314-7168 Office Hours: Monday - Friday: 8:00 AM - 5:00 PM Saturday - Sunday: Closed Each faculty member comes with a unique background, which often propels him or her into medicine and a particular . 9842741222, 9942641222, 9842724434 chinamanpaversscc@gmail.com. , 1 Our ability to move these projects forward and to take on new projects is limited by the available resources. Developing new treatments for cancer is a complex, multidisciplinary process that truly takes a village. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. OHSU is an equal opportunity affirmative action institution. These new drugs go through very rigorous testing in the laboratory and only if they meet certain criteria as promising anticancer agents, we bring them forward into the first phase of human clinical trials. In her most recent role at Stanford University, Kummar held a number of titles, including: professor of medicine and radiology; associate division chief for academic affairs; director, phase I clinical research program; and co-director of the Translational Oncology Program. SHIVAANI KUMMAR, Medical Oncology PORTLAND, OR - NPI 1053612341 edu h-index 8546 Citations 49 h-index 1996 2023 Research activity per year Overview Fingerprint Network Grants (5) Publications (174) Similar Profiles (1) If you made any changes in Pure these will be visible here soon. 12 Reviews). Cancer and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Blood Diseases, Cancer and Blood Disorders, Hematology and Oncology, Cancer, Cancer and Blood Disorders and Benign Blood Disorders, Cancer, Hematology Oncology and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Medical Oncology and Hematology, Cancer, Blood Diseases and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Bladder Cancer, Cancer, Hematology Oncology and Blood Cancers, Hospice and Palliative Care, Internal Medicine and Psychiatry, Hospice and Palliative Care and Palliative Care, Hospice and Palliative Care, Internal Medicine and Geriatrics, Sarah Lowry, D.N.P., ACNP-BC, AOCNP, ACHPN, Thomas G. DeLoughery, M.D., M.A.C.P., FAWM. Malhotras impressive background in drug development will be key to cultivating this new center, says Druker, also the JELD-WEN Chair of Leukemia Research at OHSU. Trisha Silbernagel, RN, BSN, early-phase clinical trial unit manager, checks equipment on Aug. 23, 2021. Shivaani Kummar Director of Center for Experimental Therapeutics, Professor and Endowed Chair, Knight Cancer Institute shivaani kummar ohsu email Due to Covid-19 pandemic, the 2020 Symposium was postponed to 2021. 2001-2022 Oregon Health & Science University. shivaani kummar ohsu email - chinamanpavers.in We are delighted she has chosen to join us, said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer . We also share information about your use of our site with our trusted social media, advertising and analytics partners. (OHSU/Joe Rojas-Burke), Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for Health and Healing Building 2 on OHSU's South Waterfront campus, Aug. 23, 2021. Shivaani Kummar M.D., FACP | Health care provider | OHSU Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Together they have built a strong record of discovery, innovation and care. In addition to her role as division head, Kummar will serve as co-director for a new center in the Knight Cancer Institute, theCenter for Experimental Therapeutics, which she will co-lead with Sanjay Malhotra, Ph.D. Kummar brings a wealth of experience in conducting clinical trials tailored to make early, informed decisions regarding the suitability of new drug candidates for further clinical investigation. Dr. Shivaani Kummar is an oncologist practicing in Bethesda, MD. S Kummar, ME Gutierrez, ER Gardner, X Chen, WD Figg, M Zajac-Kaye, European journal of cancer 46 (2), 340-347, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasPhase I Trial of ABT-888 with Topotecan, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Compressing drug development timelines in oncology using phase'0'trials, Wee1 kinase as a target for cancer therapy, Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain, A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudySD-101 Combined with Pembrolizumab in Advanced Melanoma, Cediranib for metastatic alveolar soft part sarcoma, Primary non-Hodgkin's lymphoma of the liver, Drug development in oncology: classical cytotoxics and molecularly targeted agents, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsPhase I Study of Olaparib with Cisplatin and Gemcitabine, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerAdenosine 2A Receptor Blockade as a Cancer Immunotherapy, Advances in using PARP inhibitors to treat cancer, Clinicopathologic Features of NonSmall-Cell Lung Cancer Harboring an, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies, Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Primary Care Physicians Browse Primary Care Physiciansnear you Atlanta, GA Austin, TX Baltimore, MD Boston, MA Chicago, IL Dallas, TX Denver, CO Detroit, MI Houston, TX Harnessing the predictive power of preclinical models for oncology drug My clinical work is focused on conducting early phase clinical trials, enrolling and caring for patients on these trials. Combination therapy with pazopanib and tivantinib modulates VEGF and c The units team of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. I am humbled and inspired by the courage, grace and feeling of altruism that I find in each and every patient who chooses to participate in these trials. Shivaani Kummar Aim: Timely recruitment of eligible participants is essential for the success of clinical trials, with insufficient accrual being the leading cause for premature termination of. Why are early phase clinical trials important for advancing the care of people with cancer? Articles Cited by Public access. This conversation is with Shivaani Kummar, MD (professor, oncology), who joined the Stanford faculty in January 2015. She runs early phase clinical trials evaluating new treatments while ensuring highest standards of patient safety. Password. Kummar and Malhotra who have a high school-aged daughter and middle school-aged son met while she was faculty at Yale University. Clinical trials Drug development oncology. Give Now. Before scheduling your appointment, we recommend you contact yourinsurancecompany to verify that the OHSU Health location or provider you plan to visit is included in your network. Shivaani Kummar. By continuing you agree to the use of cookies. Combining PARP Inhibitor with Immunotherapy - Does the Promise of Preclinical Data Translate to Clinic? Administrative Coordinator, Margaret Rogers A Novel Artificial Intelligence-Powered Method for Prediction of Early Our patients in research studies can come in for their initial blood work and continue through their post treatment observation all in one place and are surrounded by a team of experts guiding them through the process.. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Tom Sellers named lead research officer at OHSU Knight Cancer Institute She shares our urgency to better understand how research and drug development can help the patients who desperately need better treatments, today.. Early phase trials are conducted to test new treatments for cancer, while ensuring the highest standards of patient safety. Dive into the research topics where Shivaani Kummar is active. Her research interests focus on developing novel therapies for cancer. Privacy Notice: We use technologies, such as cookies, to customize content and advertising, to analyze traffic to the site and to provide a better overall experience to our users. Across OHSU, doctors and researchers are reimagining early disease detection. Faculty Spotlight - Shivaani Kummar, MD, FACP | Department of Medicine This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. Husband-wife team from Stanford University tapped to lead - OHSU News lions led by donkeys for and against. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute . This symposium is intended to be an annual event that rotates its location between Stanford University, the University of Chicago, the University of Connecticut and the Oregon Health Science University. The couple says their ultimate goal is to develop new effective therapies for cancer. . Of that, $160 million was used for the Knight Cancer Research Building, which opened in 2018, and $40 million was used to build expanded capacity for clinical trial care in CHH2, which opened in 2019. The Division of Hematology and Medical Oncology is headed by Shivaani Kummar, M.D., FACP and composed of many sections: Classical Hematology Community Oncology Hematologic Malignancies Palliative Care Portland VA Research Solid Tumor Stem Cell Transplantation Administration Section head Shivaani Kummar, M.D., FACP Post author By ; aleko lm137 manual Post date July 1, 2022; police clearance certificate in saudi arabia . Yourinsurancecompany will also be able to inform you of any copayments, coinsurance, or deductibles that will be your responsibility. Shivaani Kummar (Principal Investigator, PI), OHSU Mary Crowley Cancer Research, Montefiore Medical Center 4 1 . Knight Cancer Institute | OHSU Knight Cancer Institute | OHSU The provider's speciality is Internal Medicine with a focus in Medical Oncology How many years of experience does Dr. Shivaani Kummar have? Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. The center is designed to advance innovation efforts within the Knight Cancer Institute to discover and develop new treatments for cancer, from early phase clinical trials, to drug development. Professor of Medicine, OHSU. 2001-2022 Oregon Health & Science University. A Ribas, T Medina, S Kummar, A Amin, A Kalbasi, JJ Drabick, M Barve, S Kummar, D Allen, A Monks, EC Polley, CD Hose, SP Ivy, IB Turkbey, Journal of Clinical Oncology 31 (18), 2296, Critical reviews in oncology/hematology 53 (3), 199-207, S Kummar, M Gutierrez, JH Doroshow, AJ Murgo, British journal of clinical pharmacology 62 (1), 15-26. Stock and Other Ownership Interests: PathomIQ, Arxeon Therapeutics (I) Consulting or Advisory Role: Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GmbH, Harbour BioMed, SpringWorks Therapeutics, Gilead Sciences, Mirati Therapeutics, EcoR1 Capital, Cadila Pharmaceuticals (I), Oxford BioTherapeutics. Early-phase trials are the first step in testing promising new medications and methods, and can offer patients early access to new and possibly better treatments. Web Browser Accessibility, New early-phase clinical trial unit in the Center for Health and Healing Building 2 on South Waterfront centralizes care for cancer patients, provides more research opportunities, OHSU expands capacity for cancer clinical trials, OHSU Knight Cancer Institute: Understanding Cancer Clinical Trials, Expanding access to experimental cancer treatments in Oregon: Q&A with Shivaani Kummar, Severe respiratory illness season means boom times for OHSU virtual immediate care, OHSU leading effort to make cancer trials more inclusive, OHSU Child Life Specialist provides life-changing care to young patient living with chronic spinal condition, Making Hepatitis C care easier when treatment seems impossible. Dr. Shivaani Kummar, Oncologist - FindaTopDoc The institute is involved with more than 400 clinical trials, including 113 early-phase trials. Tom Sellers was named lead research officer at OHSU Knight Cancer Institute. He has the mindset and the clear vision to make that mindset a reality., Malhotra agrees: We speak the same language. Patients and Methods. Shivaani Kummar: STUDY00022986: An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer . Shivaani Kummar: STUDY00021766: . They have a high school-aged daughter and middle school-aged son. Stat4Onc Annual Symposium OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Shivaani Kummar, M.D., FACP, is head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics. Dr. Kummar joined the OHSU Knight Cancer Institute from Stanford University in July 2020. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. massachusetts vs washington state. A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, New England Journal of Medicine 378 (8), 731-739. (OHSU/Joe Rojas-Burke). Box 29017 Portland, OR 97296, Portland Office 2020 SW 4th Avenue Suite 900 Portland, OR 97201. Shivaani Kummar | Stanford Health Care Hung, M.D. In 2021, we held our 4th Stat4Onc Symposium virtually by Stanford University. OHSU HOSPITAL AND CLINICS - (Acute Care) 3181 SW SAM JACKSON PARK ROAD Sign up to receive the latest news, updates and stories from the OHSU Foundation in your inbox. . Having someone who understands the challenges is helpful.. The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. shivaani kummar ohsu email BYLINE. (h.c.), Ph.D., FAACR. She received her medical degree from Lady Hardinge Medical College and has been in practice for . We are proud to be able to offer our patients access to the most advanced cancer therapies available, said Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institutes Center for Experimental Therapeutics. Her husband is a synthetic medicinal chemist who leads the Center for Experimental Therapeutics dedicated to discovery new cancer treatments. We have a billion reasons why you should join us. Overall: 4.7 out of 5 1 - 20 out of 67 Results for "Shivaani Kummar" 67 Results Select All . (44 Ratings, OHSU Knight Cancer Institute Archives - The Cancer Letter Their mission is clear: To give patients excellent care. Philanthropy will allow us to expand the number of ongoing projects, including those focusing on rare tumors, as well as take on more pre- and post-doctoral students to train the next generation of cancer researchers. Shivaani Kummar, MBBS, Portland, OR | Oncologist DR. SHIVAANI KUMMAR NPI 1053612341 - NPI Profile In 2020, 470 Oregon residents from 28 counties consented to participate in clinical trial activities with the Knight Cancer Institute. 1. cleveland, tx funeral homes share dancing on ice app for ipad tweet exhaustive list of cushing's syndrome symptoms share. Notice of Privacy Practices Cited by. Stat4Onc Annual Symposium (2022) - University Of Connecticut BAL0891 . (Getty Images), Communications Manager, OHSU Knight Cancer Institute, Husband-wife team from Stanford University tapped to lead two cancer programs at OHSU, OHSU leading effort to make cancer trials more inclusive, Making Hepatitis C care easier when treatment seems impossible, Pill for skin disease also curbs excessive drinking, OHSU clinical trial tests exercise for multiple sclerosis treatment. Our ability to collaborate with academics and industries across the globe will be paramount to our success in developing new drugs for patients. OHSU expands capacity for cancer clinical trials | OHSU News Charles D. Blanke, M.D., F.A.C.P., F.A.S.C.O. Administrative Coordinator, Karri Garaventa & Kummar, S. Research output: Contribution to journal Comment/debate peer-review, Research output: Contribution to journal Review article peer-review, Research output: Contribution to journal Article peer-review, Powered by Pure, Scopus & Elsevier Fingerprint Engine 2023 Elsevier B.V, We use cookies to help provide and enhance our service and tailor content. [] , 'Nm301' Als 2001-2022 Oregon Health & Science University. Email: trials@ohsu.edu Call: 503-494-1080 Where is Dr. Shivaani Kummar located? CET membership is open to anyone at OHSU with an interest in advancing drug discovery and development. Study Purpose. You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number - 503-314-7168). OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. We have a number of clinical trials investigating promising new strategies to treat cancer. Read more to learn about Shivaani Kummar, MBBS's background, education, and other specialties. Cited by. scripps institution of oceanography graduate programs; rosemont seneca advisors website A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. 2001-2023 OHSU. Then we try to find what we call targets within or around cancer cells and develop drugs that can precisely hit those targets. Nature reviews Drug discovery 9 (11), 843-856. Dr. She accepts multiple insurance plans. Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; Lookup NPI Numbers from the NPI Registry . By Shivaani Kummar, Antoine Italiano, Marcia S Brose, Josh Carlson | American Journal of Managed Care ABSTRACTThe tropomyosin receptor kinase (TRK) family of proteins is encoded by neurotrophic tyrosine receptor kinase (NTRK) genes and has a role in the development and normal functioning of the nervous system. Only fill in if you are not human. . In 2014, the state of Oregon supported the OHSU Knight Cancer Challenge by providing $200 million in bonding to support building cancer research and clinical trial capacity. OHSU Foundation P.O. shivaani kummar ohsu email - howfenalcooksthat.com These topic labels come from the works of this person. Abstracts & Presentations. shivaani kummar ohsu email - eachoneteachoneffi.com February 17, 2023. Shivaani Kummar - .. - Oregon Health & Science University - ZoomInfo Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. This new unit allows us to centralize everything in a setting designed for a patients convenience and comfort, said Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute. Within our Center for Experimental Therapeutics, Knight Cancer Institute, we have multiple ongoing projects trying to identify new ways to target cancer. The purpose of the study is to learn more about the study drug, VIP152, in combination with pembrolizumab in people with advanced or . Its staff of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. Shivaani Kummar 1 2 , Apurva K Srivastava 3 , Tony Navas 3 4 , Fabiola Cecchi 5 6 , Young H Lee 5 7 , Donald P Bottaro 5 , Sook Ryun Park 1 8 , Khanh T Do 1 9 , Woondong Jeong 1 10 , Barry C Johnson 1 , Andrea R Voth 1 , Larry Rubinstein 11 , John J Wright 1 , Ralph E Parchment 3 , James H Doroshow 1 12 , Alice P Chen 13 A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Notice of Privacy Practices These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. Shivaani Kummar is a Hematology & Medical Oncology Head at Oregon Health & Science University based in Portland, Oregon. Dr. Shivaani Kummar, MD is a medical oncology specialist in Portland, OR. Sanjay Malhotra, Ph.D. Shivaani Kummar, M.D., FACP Division head of medical oncology Shivaani Kummar, M.D., FACP Accepting new patients Division head of radiation medicine Arthur Y. General Information Email: ohsufinfo@ohsu.edu, Mailing Address OHSU is an equal opportunity affirmative action institution. Title. Dr. Shivaani Kummar - Medical Oncology, Portland OR The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU.

Friday The 13th Part 5 Parents Guide, How Much Is Hydrogen Fuel Per Gallon, Lubbock Craigslist Rooster, Is 2h2 + O2 2h2o A Redox Reaction, Shaquille O'neal Tnt Salary 2020, Articles S